CA2448319A1 - Cytotoxins, prodrugs, linkers and stabilizers useful therefor - Google Patents
Cytotoxins, prodrugs, linkers and stabilizers useful therefor Download PDFInfo
- Publication number
- CA2448319A1 CA2448319A1 CA002448319A CA2448319A CA2448319A1 CA 2448319 A1 CA2448319 A1 CA 2448319A1 CA 002448319 A CA002448319 A CA 002448319A CA 2448319 A CA2448319 A CA 2448319A CA 2448319 A1 CA2448319 A1 CA 2448319A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- unsubstituted
- compound according
- member selected
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Abstract
The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleave d in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.
Claims (47)
1. A compound having the structure:
wherein X and Z are members independently selected from O, S and NR23 wherein R23 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and acyl;
R1 is H, substituted or unsubstituted lower alkyl, or C(O)R8, wherein R8 is a member selected from NR9R10 and OR9, in which R9, and R10 are members independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;
R2 is H, or substituted or unsubstituted lower alkyl;
R3 is a member selected from (=O), and OR11, wherein R11 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, acyl, C(O)R12R13, C(O)OR12, C(O)NR12R13, C(O)OR12, P(O)(OR12)2, C(O)CHR12R13, C(O)OR12 and SiR12R13R14, in which R12, R13, and R14 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted aryl, wherein R12 and R13 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms, and one or more of R12, R13, and R14 optionally comprises an enzymatically cleaveable group;
R4 and R5 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, halogen, NO2, NR15R16, NC(O)R15, OC(O)NR15R16, OC(O)OR15, C(O)R15, OR15 wherein R15 and R16 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl and substituted or unsubstituted peptidyl, wherein R15 and R16 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms;
R6 is a single bond which is either present or absent and when present R6 and R7 are joined to form a cyclopropyl ring; and R7 is CH2-X1 or -CH2- joined in said cyclopropyl ring with R7, wherein X1 is a leaving group.
wherein X and Z are members independently selected from O, S and NR23 wherein R23 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and acyl;
R1 is H, substituted or unsubstituted lower alkyl, or C(O)R8, wherein R8 is a member selected from NR9R10 and OR9, in which R9, and R10 are members independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;
R2 is H, or substituted or unsubstituted lower alkyl;
R3 is a member selected from (=O), and OR11, wherein R11 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, acyl, C(O)R12R13, C(O)OR12, C(O)NR12R13, C(O)OR12, P(O)(OR12)2, C(O)CHR12R13, C(O)OR12 and SiR12R13R14, in which R12, R13, and R14 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted aryl, wherein R12 and R13 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms, and one or more of R12, R13, and R14 optionally comprises an enzymatically cleaveable group;
R4 and R5 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, halogen, NO2, NR15R16, NC(O)R15, OC(O)NR15R16, OC(O)OR15, C(O)R15, OR15 wherein R15 and R16 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl and substituted or unsubstituted peptidyl, wherein R15 and R16 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms;
R6 is a single bond which is either present or absent and when present R6 and R7 are joined to form a cyclopropyl ring; and R7 is CH2-X1 or -CH2- joined in said cyclopropyl ring with R7, wherein X1 is a leaving group.
2. The compound according to claim 1, wherein R2 is other than CF3.
3. The compound according to claim 1, wherein said leaving group is a member selected from azide, halogen, alkylsulfonyl and arylsulfonyl.
4. The compound according to claim 3, wherein said leaving group is Cl or Br.
5. The compound according to claim 1, wherein R1 is CO2CH3.
6. The compound according to claim 1, wherein R2 is CH3.
7. The compound according to claim 1, wherein R1 is CO2CH3, and R2 is CH3.
8. The compound according to claim 7, wherein R4 and R5 are members independently selected from H, halogen, NH2, O(CH2)2N(Me)2 and NO2.
9. The compound according to claim 1, wherein at least one of R4 and R5 is other than a member selected from H and OCH3.
10. The compound according to claim 1, wherein at least one of R4, R5, R15 and R16 comprises a cleaveable disulfide group.
11. The compound according to claim 1, wherein at least one of R4, R5, R15 and R16 comprises:
wherein R30 is a member selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;
R31 and R32 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl, or R31 and R32 together are:
wherein R33 and R34 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;
R35 is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and NR36 wherein R36 is a member selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and X5 is O or NR37 wherein R37 is a member selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl.
wherein R30 is a member selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;
R31 and R32 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl, or R31 and R32 together are:
wherein R33 and R34 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;
R35 is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and NR36 wherein R36 is a member selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and X5 is O or NR37 wherein R37 is a member selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl.
12. The compound according to claim 11, wherein at least one of R31, R32 R33 and R34 is substituted with a member selected from targeting agents and detectable labels.
13. The compound according to claim 12, wherein said targeting agent is an antibody.
14. The compound according to claim 1, wherein at least one member selected from R4, R5, R15 and R16 comprises a targeting agent or a detectable label.
15. The compound according to claim 14, wherein said targeting agent is an antibody.
16. The compound according to claim 7, having the structure:
17. The compound according to claim 7, wherein X is O; and Z is O.
18. The compound according to claim 1, wherein a member selected from R4 and R5 is:
wherein X2 and Zl are members independently selected from O, S and NR23.
R17 and Rl8 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, halogen, NO2,NR19R20, NC(O)R19, OC(O)NRl9, OC(O)OR19, C(O)R19, OR19 wherein R19 and R20 are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted peptidyl, wherein R19 and R20 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms, and one or more members selected from R19 and R20 comprise a cleaveable group.
wherein X2 and Zl are members independently selected from O, S and NR23.
R17 and Rl8 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, halogen, NO2,NR19R20, NC(O)R19, OC(O)NRl9, OC(O)OR19, C(O)R19, OR19 wherein R19 and R20 are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted peptidyl, wherein R19 and R20 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms, and one or more members selected from R19 and R20 comprise a cleaveable group.
19. The compound according to claim 18, wherein when Zl is NH, both Rl7 and Rl8 are not H; and Rl7 is not NH2.
20. The compound according to claim 18, wherein X2 is O; and Zl is a member selected from O and NR23.
21. The compound according to claim 1, wherein R11 is a peptidyl moiety having the structure:
wherein X3 is a member selected from protected or unprotected reactive functional groups, detectable labels and targeting agents;
L1 is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
AA1, AAb and AAb+1 are members independently selected from natural and unnatural a-amino acids;
L2 is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
q and v are integers independently selected from 0 and 1; and b is an integer from 0 to 20.
wherein X3 is a member selected from protected or unprotected reactive functional groups, detectable labels and targeting agents;
L1 is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
AA1, AAb and AAb+1 are members independently selected from natural and unnatural a-amino acids;
L2 is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
q and v are integers independently selected from 0 and 1; and b is an integer from 0 to 20.
22. The compound according to claim 21, wherein at least one member selected from L3 and L4 comprises a poly(ethylene glycol) moiety.
23. The compound according to claim 21, wherein said peptidyl moiety has the structure:
wherein R21 and R22 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, detectable labels and targeting agents;
R25 is a members selected from H, substituted or unsubstituted lower alkyl, an amino acid side chain, detectable labels, and targeting agents; and s is an integer from 0 to 20.
wherein R21 and R22 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, detectable labels and targeting agents;
R25 is a members selected from H, substituted or unsubstituted lower alkyl, an amino acid side chain, detectable labels, and targeting agents; and s is an integer from 0 to 20.
24. The compound according to claim 21, wherein c is an integer between 1 and 5.
25. The compound according to claim 21, wherein at least one member selected from R15 and R16 has the structure:
wherein X4 is member selected from protected or unprotected reactive functional groups, detectable labels and targeting agents;
L3 is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
AA1, AA c and AA c+1 are members independently selected from natural and unnatural .alpha.-amino acids;
L4 is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
R24 is a member selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
p and t are integers independently selected from 0 and 1; and c is an integer from 0 to 20.
wherein X4 is member selected from protected or unprotected reactive functional groups, detectable labels and targeting agents;
L3 is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
AA1, AA c and AA c+1 are members independently selected from natural and unnatural .alpha.-amino acids;
L4 is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
R24 is a member selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
p and t are integers independently selected from 0 and 1; and c is an integer from 0 to 20.
26. The compound according to claim 25, wherein at least one member selected from L1 an L2 comprises a poly(ethylene glycol) moiety.
27. The compound according to claim 25, wherein said member has the structure:
wherein R27 and R28 are members independently selected from H, substituted or unsubstituted lower alkyl, amino acid side chains, detectable labels and targeting agents.
wherein R27 and R28 are members independently selected from H, substituted or unsubstituted lower alkyl, amino acid side chains, detectable labels and targeting agents.
28. The compound according to claim 25, wherein c is an integer from 1 to 5.
29. The compound according to claim 1 or 25, wherein R11 has the structure:
wherein X4 is a member selected from protected reactive functional groups, unprotected reactive functional groups, detectable labels and targeting agents;
L3 is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
L4 is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups; and p and t are integers independently selected from 0 and 1.
wherein X4 is a member selected from protected reactive functional groups, unprotected reactive functional groups, detectable labels and targeting agents;
L3 is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups;
L4 is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl groups; and p and t are integers independently selected from 0 and 1.
30. The compound according to claim 29, wherein L4 is a substituted or unsubstituted ethylene moiety.
31. The compound according to claim 29, wherein X4 is a member selected from R29, COOR29, C(O)NR29, and C(O)NNR29 wherein R29 is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted heteroaryl.
32. The compound according to claim 31, wherein R29 is a member selected from: H; OH; NHNH2;
wherein R30 is a member selected from substituted or unsubstituted alkyl terminated with a reactive functional group, substituted or unsubstituted heteroaryl terminated with a functional group and -(L3)p X4, wherein each L3, X4 and p are independently selected.
wherein R30 is a member selected from substituted or unsubstituted alkyl terminated with a reactive functional group, substituted or unsubstituted heteroaryl terminated with a functional group and -(L3)p X4, wherein each L3, X4 and p are independently selected.
33. The compound according to claim 21, 25, or 29, wherein said detectable label is a fluorophore.
34. The compound according to claim 21, 25, or 29, wherein said targeting agent is a biomolecule.
35. The compound according to claim 34, wherein said biomolecule is a member selected from antibodies, receptors, peptides, lectins, saccharides, nucleic acids and combinations thereof.
36. The compound according to claim 1, wherein at least one of R15 and R16 bears a reactive group appropriate for conjugating said compound to another molecule.
37. The compound according to claim 36 wherein at least one of R15 and R16 is a member selected from substituted alkyl and substituted heteroalkyl, said member having said reactive functional group at its free terminus.
38. The compound according to claim 36, wherein said compound is conjugated to said another molecule via said reactive functional group.
39. The compound according to claim 1, wherein one of R15 and R16 comprises a cleaveable moiety.
40. The compound according to claim 27, wherein at least one of R21 and R22 bears a reactive functional group appropriate for conjugating said compound to another molecule.
41. The compound according to claim 36 wherein at least one of R21 and R22 is a member selected from substituted alkyl and substituted heteroalkyl, said member having said reactive functional group at its free terminus.
42. The compound according to claim 36, wherein said compound is conjugated to said another molecule via said reactive functional group.
43. A pharmaceutical formulation comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
44. A method of killing a cell, said method comprising administering to said cell an amount of a compound according to claim 1 sufficient to kill said cell.
45. A method of killing a carcinoma cell in a subject bearing said cell, said method comprising administering to said subject an amount of a compound according to claim 1, sufficient to kill said cell.
46. A method of retarding or stopping the growth a tumor in a mammalian subject, said method comprising administering to said subject an amount of a compound according to claim 1, sufficient to retard or stop said growth.
47. A compound having the structure:
in which ring system A is a member selected from substituted or unsubstituted aryl substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocycloalkyl groups;
E and G are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, a heteroatom, or a single bond, and E and G are optionally joined to form a ring system selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocycloalkyl;
X is a member selected from O, S and NR23, R23 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and acyl;
R3 is a member selected from (=O), SR11 and OR11 in which R11 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, acyl, C(O)R12, C(O)OR12, C(O)NR12R13, C(O)OR12, P(O)(OR12)2, C(O)CHR12R13, C(O)OR12 or SiR12R13R14, and R11 optionally comprises an enzymatically cleaveable group wherein R12, R13, and R14 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted aryl, wherein R12 and R13 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms, and one or more of R12, R13, or R14 optionally comprises an enzymatically cleaveable group; and R4 and R5 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, halogen, NO2, NR15R16, NC(O)R15, OC(O)NR15R16, OC(O)OR15, C(O)R15, SR15 and OR15. R15 and R16 independently represent H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl and substituted or unsubstituted peptidyl, wherein R15 and R16 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms, and one or more of R4, R5, R15 and R16 optionally comprise an enzymatically cleaveable group.
in which ring system A is a member selected from substituted or unsubstituted aryl substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocycloalkyl groups;
E and G are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, a heteroatom, or a single bond, and E and G are optionally joined to form a ring system selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocycloalkyl;
X is a member selected from O, S and NR23, R23 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and acyl;
R3 is a member selected from (=O), SR11 and OR11 in which R11 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, acyl, C(O)R12, C(O)OR12, C(O)NR12R13, C(O)OR12, P(O)(OR12)2, C(O)CHR12R13, C(O)OR12 or SiR12R13R14, and R11 optionally comprises an enzymatically cleaveable group wherein R12, R13, and R14 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or unsubstituted aryl, wherein R12 and R13 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms, and one or more of R12, R13, or R14 optionally comprises an enzymatically cleaveable group; and R4 and R5 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, halogen, NO2, NR15R16, NC(O)R15, OC(O)NR15R16, OC(O)OR15, C(O)R15, SR15 and OR15. R15 and R16 independently represent H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl and substituted or unsubstituted peptidyl, wherein R15 and R16 together with the nitrogen atom to which they are attached are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 4 to 6 members, optionally containing two or more heteroatoms, and one or more of R4, R5, R15 and R16 optionally comprise an enzymatically cleaveable group.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29519601P | 2001-05-31 | 2001-05-31 | |
US29525901P | 2001-05-31 | 2001-05-31 | |
US29534201P | 2001-05-31 | 2001-05-31 | |
US60/295,342 | 2001-05-31 | ||
US60/295,259 | 2001-05-31 | ||
US60/295,196 | 2001-05-31 | ||
US30490801P | 2001-07-11 | 2001-07-11 | |
US60/304,908 | 2001-07-11 | ||
PCT/US2002/017210 WO2002096910A1 (en) | 2001-05-31 | 2002-05-31 | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2448319A1 true CA2448319A1 (en) | 2002-12-05 |
CA2448319C CA2448319C (en) | 2010-07-27 |
Family
ID=27501653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2448319A Expired - Fee Related CA2448319C (en) | 2001-05-31 | 2002-05-31 | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
Country Status (11)
Country | Link |
---|---|
US (8) | US7129261B2 (en) |
EP (2) | EP1434778A4 (en) |
JP (2) | JP4961095B2 (en) |
KR (1) | KR20030033007A (en) |
CN (2) | CN101671335A (en) |
AU (1) | AU2002303929B9 (en) |
CA (1) | CA2448319C (en) |
IL (2) | IL154183A0 (en) |
MX (1) | MXPA03011094A (en) |
NZ (1) | NZ529788A (en) |
WO (1) | WO2002096910A1 (en) |
Families Citing this family (225)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7425541B2 (en) * | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
WO2002067930A1 (en) * | 2001-02-22 | 2002-09-06 | School Of Pharmacy, University Of London | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment |
WO2002092771A2 (en) | 2001-05-11 | 2002-11-21 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
CN101671335A (en) * | 2001-05-31 | 2010-03-17 | 梅达莱克斯公司 | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
WO2003106429A1 (en) * | 2002-06-14 | 2003-12-24 | 武田薬品工業株式会社 | Prodrug and process for producing the same |
US20040249130A1 (en) * | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
DE60203491D1 (en) * | 2002-08-02 | 2005-05-04 | Inst Curie Paris | Shiga toxin subunit B as a vector for diagnosis of tumors and drug delivery to GB3-expressing tumors |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
EP2143481A1 (en) * | 2003-02-19 | 2010-01-13 | Natrix Separations Inc. | Composite materials comprising supported porous gels |
ZA200507752B (en) * | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
SG173223A1 (en) | 2003-04-22 | 2011-08-29 | Ipsen Pharma Sas | Peptide vectors |
CA2536357A1 (en) | 2003-05-29 | 2004-12-23 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
CA2534298C (en) * | 2003-08-01 | 2013-12-31 | Nobex Corporation | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same |
US8883147B2 (en) | 2004-10-21 | 2014-11-11 | Xencor, Inc. | Immunoglobulins insertions, deletions, and substitutions |
US20060134105A1 (en) * | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
AU2005231532B2 (en) | 2004-04-08 | 2010-01-07 | Merck Millipore Ltd. | Membrane stacks |
US20050239864A1 (en) * | 2004-04-23 | 2005-10-27 | Yuqiang Wang | Novel tumor-selective chemotherapeutic agents |
BRPI0510909A2 (en) * | 2004-05-19 | 2008-12-16 | Medarex Inc | cytotoxic drug-binder binding compound, pharmaceutical formulation, method for killing a cell and method for retarding or stopping tumor growth |
US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
US8133840B2 (en) * | 2004-06-07 | 2012-03-13 | Natrix Separations Inc. | Stable composite material comprising supported porous gels |
CN101010106A (en) * | 2004-06-30 | 2007-08-01 | 诺瓦提斯公司 | Conjugates of antibody and Duocarmycin derivatives as antitumor agents |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP2325207B1 (en) | 2004-11-12 | 2017-03-15 | Xencor, Inc. | FC variants with altered binding to FCRN |
CN101124249B (en) * | 2005-02-18 | 2011-06-29 | 米德列斯公司 | Human monoclonal antibodies to prostate specific membrane antigen(PSMA) |
US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
CA2605778A1 (en) | 2005-04-20 | 2006-10-26 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
SI1896040T1 (en) | 2005-06-29 | 2012-12-31 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
CA2623236A1 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
AU2006294554B2 (en) | 2005-09-26 | 2013-03-21 | E. R. Squibb & Sons, L.L.C. | Antibody-drug conjugates and methods of use |
ES2375843T3 (en) | 2005-10-26 | 2012-03-06 | Medarex, Inc. | PROCEDURES AND COMPOUNDS FOR THE PREPARATION OF ANC? LOGOS OF CC-1065. |
WO2007059404A2 (en) * | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
PL1957539T3 (en) | 2005-12-08 | 2013-08-30 | Squibb & Sons Llc | Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use |
CA2638902C (en) | 2005-12-08 | 2014-09-23 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies |
US20090175886A1 (en) | 2006-01-17 | 2009-07-09 | Medarex, Inc. | Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues |
US9603941B2 (en) * | 2006-01-24 | 2017-03-28 | Minghui Chai | Method of preparing dendritic drugs |
CA2641899A1 (en) * | 2006-02-02 | 2007-08-09 | Syntarga B.V. | Water-soluble cc-1065 analogs and their conjugates |
ME01786B (en) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimized antibodies that target cd19 |
CN101627055A (en) | 2006-09-05 | 2010-01-13 | 梅达雷克斯公司 | The antibody of bone morphogenetic protein and acceptor thereof and their using method |
KR20150067395A (en) | 2006-12-01 | 2015-06-17 | 메다렉스, 엘.엘.시. | Human antibodies that bind cd22 and uses thereof |
CL2007003622A1 (en) | 2006-12-13 | 2009-08-07 | Medarex Inc | Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method. |
NZ578354A (en) * | 2006-12-14 | 2012-01-12 | Medarex Inc | Antibody-partner molecule conjugates that bind cd70 and uses thereof |
WO2008083101A1 (en) * | 2006-12-26 | 2008-07-10 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs for the treatment of cancer |
TWI412367B (en) | 2006-12-28 | 2013-10-21 | Medarex Llc | Chemical linkers and cleavable substrates and conjugates thereof |
EP2126127B1 (en) * | 2007-01-25 | 2016-09-28 | Dana-Farber Cancer Institute, Inc. | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
AR065404A1 (en) * | 2007-02-21 | 2009-06-03 | Medarex Inc | PHARMACO-BINDING CONJUGATES, THOSE WHO JOIN POWERFUL CYTOTOXINS, PHARMACEUTICAL COMPOSITION THAT CONTAIN THEM AND THEIR USE TO DELAY OR STOP THE GROWTH OF A TUMOR IN A MAMMER |
AU2008227123B2 (en) * | 2007-03-15 | 2014-03-27 | Ludwig Institute For Cancer Research Ltd. | Treatment method using EGFR antibodies and src inhibitors and related formulations |
EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
EP2188311B1 (en) | 2007-08-14 | 2016-10-05 | Ludwig Institute for Cancer Research Ltd. | Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof |
WO2009026274A1 (en) | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
EP2195017B1 (en) | 2007-10-01 | 2014-10-22 | Bristol-Myers Squibb Company | Human antibodies that bind mesothelin, and uses thereof |
US20090118031A1 (en) * | 2007-11-01 | 2009-05-07 | Qualizza Gregory K | Shaft Structure with Configurable Bending Profile |
AR069746A1 (en) * | 2007-11-30 | 2010-02-17 | Medarex Inc | ANTI-RG-1 ANTIBODY CONJUGATES |
US20110152252A1 (en) * | 2007-12-18 | 2011-06-23 | Institut Curie | Shiga toxin b-subunit/chemotherapeutics conjugates |
HUE024903T2 (en) | 2007-12-26 | 2016-02-29 | Xencor Inc | Fc variants with altered binding to fcrn |
US8246538B2 (en) * | 2008-02-28 | 2012-08-21 | K2M, Inc. | Minimally invasive retractor with separable blades and methods of use |
CA2946445C (en) | 2008-05-20 | 2019-01-08 | Acorda Therapeutics, Inc. | Hepatoprotectant acetaminophen mutual prodrugs |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
EP2334413A4 (en) * | 2008-09-02 | 2013-09-18 | Natrix Separations Inc | Chromatography membranes, devices containing them, and methods of use thereof |
BRPI0921687A8 (en) | 2008-11-03 | 2022-11-08 | Syntarga Bv | COMPOUND, CONJUGATE, USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION, PROCESS FOR PREPARING A PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING A MAMMAL IN NEED THEREOF, AND, METHOD FOR TREATING OR PREVENTING A TUMOR IN A MAMMAL. |
WO2010096394A2 (en) * | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
PT2403878T (en) | 2009-03-05 | 2017-09-01 | Squibb & Sons Llc | Fully human antibodies specific to cadm1 |
EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
NZ595792A (en) | 2009-04-20 | 2014-01-31 | Oxford Biotherapeutics Ltd | Antibodies specific to cadherin-17 |
US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
EP2470569A1 (en) | 2009-10-13 | 2012-07-04 | Oxford Biotherapeutics Ltd. | Antibodies against epha10 |
WO2011054007A1 (en) | 2009-11-02 | 2011-05-05 | Oxford Biotherapeutics Ltd. | Ror1 as therapeutic and diagnostic target |
IN2012DN05130A (en) * | 2009-11-13 | 2015-10-23 | Natrix Separations Inc | |
HUE028629T2 (en) | 2009-12-23 | 2016-12-28 | Synimmune Gmbh | Anti-flt3 antibodies and methods of using the same |
WO2011089211A1 (en) | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
WO2011103421A1 (en) * | 2010-02-18 | 2011-08-25 | Shuber Anthony P | Compositions and methods for treating cancer |
ES2815678T3 (en) * | 2010-04-21 | 2021-03-30 | Syntarga Bv | Conjugates of CC-1065 Analogs and Bifunctional Linkers |
JP6082344B2 (en) | 2010-05-27 | 2017-02-15 | ゲンマブ エー/エス | Monoclonal antibody against HER2 epitope |
EP2576621B1 (en) | 2010-05-27 | 2019-04-10 | Genmab A/S | Monoclonal antibodies against her2 |
RS56599B1 (en) | 2010-06-15 | 2018-02-28 | Genmab As | Human antibody drug conjugates against tissue factor |
DK3029066T3 (en) | 2010-07-29 | 2019-05-20 | Xencor Inc | ANTIBODIES WITH MODIFIED ISOELECTRIC ITEMS |
US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
EP2621954A1 (en) | 2010-10-01 | 2013-08-07 | Oxford Biotherapeutics Ltd. | Anti-rori antibodies |
JOP20210044A1 (en) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
EP2663647A4 (en) | 2011-01-14 | 2015-08-19 | Redwood Bioscience Inc | Aldehyde-tagged immunoglobulin polypeptides and method of use thereof |
JP6239979B2 (en) * | 2011-03-04 | 2017-11-29 | ニューヨーク・ユニバーシティ | Hydrogen-bonded alternative macrocycles as regulators of RAS |
CN103796678B (en) | 2011-04-20 | 2018-02-27 | 健玛保 | For HER2 bispecific antibody |
WO2012158896A2 (en) | 2011-05-17 | 2012-11-22 | Natrix Separations Inc. | Layered tubular membranes for chromatography, and methods of use thereof |
US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
JP5926374B2 (en) | 2011-06-10 | 2016-05-25 | メルサナ セラピューティクス,インコーポレイティド | Protein-polymer-drug conjugate |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
CA2840537C (en) | 2011-06-28 | 2021-12-14 | Oxford Biotherapeutics Ltd. | Antibodies to adp-ribosyl cyclase 2 |
SI2726094T1 (en) | 2011-06-28 | 2017-04-26 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
UA117901C2 (en) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Antibody variants and uses thereof |
WO2013022855A1 (en) | 2011-08-05 | 2013-02-14 | Xencor, Inc. | Antibodies with modified isoelectric points and immunofiltering |
US9963481B2 (en) | 2011-09-07 | 2018-05-08 | The Scripps Research Institute | Chiral oligomeric pentenoate amides as bio-oligomer mimetics |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
AU2012323287B2 (en) | 2011-10-10 | 2018-02-01 | Xencor, Inc. | A method for purifying antibodies |
EP2592103A1 (en) | 2011-11-08 | 2013-05-15 | Adriacell S.p.A. | Polymer aldehyde derivatives |
DK2814829T3 (en) | 2012-02-13 | 2017-03-20 | Bristol Myers Squibb Co | RELATIONSHIPS, CONJUGATES THEREOF AND USES AND RELATED PROCEDURES |
EP2836494B1 (en) | 2012-04-05 | 2019-08-21 | Nerviano Medical Sciences S.r.l. | New alkylating agents |
US20150087688A1 (en) * | 2012-04-25 | 2015-03-26 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
IN2014MN02164A (en) | 2012-04-27 | 2015-08-28 | Cytomx Therapeutics Inc | |
AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
WO2014006217A1 (en) | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
GB201213652D0 (en) | 2012-08-01 | 2012-09-12 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
WO2014027959A1 (en) | 2012-08-14 | 2014-02-20 | Nanyang Technological University | Angiopoietin-like 4 antibody and a method of its use in cancer treatment |
US20140161790A1 (en) | 2012-11-19 | 2014-06-12 | Xencor, Inc. | Engineered immunoglobulins with extended in vivo half-life |
CA2891280C (en) | 2012-11-24 | 2018-03-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
KR20200134340A (en) | 2013-01-10 | 2020-12-01 | 젠맵 비. 브이 | Human igg1 fc region variants and uses thereof |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
WO2014110601A1 (en) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Novel heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
CN103933575B (en) | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | A kind of three flute profile connexons and its application |
GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
LT2956173T (en) | 2013-02-14 | 2017-06-26 | Bristol-Myers Squibb Company | Tubulysin compounds, methods of making and use |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
EP3587448B1 (en) | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
ES2738657T3 (en) * | 2013-09-25 | 2020-01-24 | Nerviano Medical Sciences Srl | Thieno [2,3-e] indole derivatives as new antitumor |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
CN105813655B (en) | 2013-10-11 | 2022-03-15 | 阿萨纳生物科技有限责任公司 | Protein-polymer-drug conjugates |
EP3055331B1 (en) | 2013-10-11 | 2021-02-17 | Oxford Bio Therapeutics Limited | Conjugated antibodies against ly75 for the treatment of cancer |
ES2726850T3 (en) | 2013-10-11 | 2019-10-09 | Mersana Therapeutics Inc | Protein-polymer-drug conjugates |
WO2015066279A2 (en) | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
WO2015089283A1 (en) | 2013-12-11 | 2015-06-18 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
CN105899235B (en) | 2014-01-10 | 2019-08-30 | 斯索恩生物制药有限公司 | Method for purifying the antibody-drug conjugates of CYS connection |
DK2948183T3 (en) | 2014-01-10 | 2016-06-27 | Synthon Biopharmaceuticals Bv | DUOCARMYCIN ADCS USED IN TREATMENT OF ENDOMETRY CANCER |
LT3069735T (en) * | 2014-01-10 | 2018-06-11 | Synthon Biopharmaceuticals B.V. | Duocarmycin adcs for use in the treatment of bladder cancer |
EP3122757B1 (en) | 2014-02-28 | 2023-09-06 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
AU2015231210B2 (en) | 2014-03-20 | 2019-09-12 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
CR20160506A (en) | 2014-03-28 | 2017-03-10 | Xencor Inc | Bispecific Antibodies that bind to CD38 and CD3 |
WO2015187835A2 (en) | 2014-06-06 | 2015-12-10 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
NZ728019A (en) | 2014-07-11 | 2022-09-30 | Genmab As | Antibodies binding axl |
AU2015292326A1 (en) | 2014-07-24 | 2017-02-23 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
CA2968382A1 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
US11229713B2 (en) | 2014-11-25 | 2022-01-25 | Bristol-Myers Squibb Company | Methods and compositions for 18F-radiolabeling of biologics |
WO2016086021A1 (en) | 2014-11-25 | 2016-06-02 | Bristol-Myers Squibb Company | Novel pd-l1 binding polypeptides for imaging |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
CA2968878A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
DK3223845T3 (en) | 2014-11-26 | 2021-08-16 | Xencor Inc | HETERODIMERING ANTIBODIES BINDING CD3 AND CD20 |
PT3233912T (en) | 2014-12-19 | 2021-08-09 | Regenesance B V | Antibodies that bind human c6 and uses thereof |
EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
ES2747386T3 (en) | 2015-01-14 | 2020-03-10 | Bristol Myers Squibb Co | Heteroarylene-linked benzodiazepine dimers, conjugates thereof and methods of preparation and use |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
WO2016164578A1 (en) | 2015-04-07 | 2016-10-13 | Memorial Sloan Kettering Cancer Center | Nanoparticle immunoconjugates |
CN106279352B (en) | 2015-05-29 | 2020-05-22 | 上海新理念生物医药科技有限公司 | Derivative of dolastatin 10 and application thereof |
RS60141B1 (en) | 2015-07-10 | 2020-05-29 | Genmab As | Axl-specific antibody-drug conjugates for cancer treatment |
CN113350518A (en) | 2015-07-12 | 2021-09-07 | 杭州多禧生物科技有限公司 | Conjugated bridge linkers to cell binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
WO2017053619A1 (en) | 2015-09-23 | 2017-03-30 | Bristrol-Myers Squibb Company | Glypican-3binding fibronectin based scafflold molecules |
JP6412906B2 (en) | 2015-11-03 | 2018-10-24 | 財團法人工業技術研究院Industrial Technology Research Institute | Compound, linker-drug and ligand-drug complex |
EA201891121A1 (en) | 2015-11-19 | 2018-12-28 | Бристол-Майерс Сквибб Компани | ANTIBODIES TO THE GLUKORTIKOID-INDUCED RECEPTOR OF THE TUMOR NECROSIS FACTOR (GITR) AND THEIR APPLICATIONS |
CN106729743B (en) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | anti-ErbB 2 antibody-drug conjugate, and composition, preparation method and application thereof |
CN108699136B (en) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | Heterodimeric antibodies that bind CD3 and PSMA |
IL295230A (en) | 2016-03-04 | 2022-10-01 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
JP2019515677A (en) | 2016-04-26 | 2019-06-13 | アール.ピー.シェーラー テクノロジーズ エルエルシー | Antibody conjugates and methods of making and using the same |
WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
EP3463486A1 (en) | 2016-06-01 | 2019-04-10 | Bristol-Myers Squibb Company | Pet imaging with pd-l1 binding polypeptides |
ES2963807T3 (en) | 2016-06-08 | 2024-04-02 | Xencor Inc | Treatment of IgG4-related diseases with anti-CD19 antibodies cross-linking to CD32B |
WO2017218707A2 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
CN116063545A (en) | 2016-06-28 | 2023-05-05 | Xencor股份有限公司 | Heterodimeric antibodies that bind somatostatin receptor 2 |
SG11201900026TA (en) | 2016-07-14 | 2019-01-30 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
KR102493853B1 (en) | 2016-08-19 | 2023-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of manufacture and use |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
EP3526241A1 (en) | 2016-10-14 | 2019-08-21 | Xencor, Inc. | Il15/il15r heterodimeric fc-fusion proteins |
WO2018075842A1 (en) | 2016-10-20 | 2018-04-26 | Bristol-Myers Squibb Company | Condensed benzodiazepine derivatives and conjugates made therefrom |
JP7277363B2 (en) | 2016-11-01 | 2023-05-18 | ジェンマブ ビー.ブイ. | Polypeptide variants and uses thereof |
JP7138350B2 (en) | 2016-11-14 | 2022-09-16 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. | Conjugate conjugates, cell-binding molecule-drug conjugates containing the conjugates, and methods of using and producing the conjugates and conjugates |
MX2019009117A (en) | 2017-02-17 | 2019-09-13 | Bristol Myers Squibb Co | Antibodies to alpha-synuclein and uses thereof. |
CN110621337B (en) | 2017-05-10 | 2021-11-09 | 浙江时迈药业有限公司 | anti-LAG 3 human monoclonal antibodies and uses thereof |
CN116333129A (en) | 2017-05-25 | 2023-06-27 | 百时美施贵宝公司 | Antibodies comprising modified heavy chain constant regions |
CN111132733A (en) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15R α and an antigen binding domain |
US11566044B2 (en) | 2017-07-26 | 2023-01-31 | The University Of Queensland | Disulfide bond containing compounds and uses thereof |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
US11312770B2 (en) | 2017-11-08 | 2022-04-26 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CA3084092A1 (en) * | 2017-12-06 | 2019-06-13 | Ontario Institute For Cancer Research (Oicr) | Acyl hydrazone linkers, methods and uses thereof |
CA3086199A1 (en) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
EP3728273A4 (en) | 2017-12-22 | 2021-12-29 | Ontario Institute for Cancer Research (OICR) | Heterocyclic acyl hydrazone linkers, methods and uses thereof |
WO2019140229A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
EP3743440A1 (en) | 2018-01-24 | 2020-12-02 | Genmab B.V. | Polypeptide variants and uses thereof |
WO2019183551A1 (en) | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
US11155618B2 (en) | 2018-04-02 | 2021-10-26 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
KR20210010862A (en) | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-fusion protein and PD-1 targeting heterodimer fusion protein containing PD-1 antigen binding domain and uses thereof |
WO2019204655A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
US11485741B2 (en) | 2018-04-24 | 2022-11-01 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (TLR7) agonists |
WO2020003210A1 (en) | 2018-06-29 | 2020-01-02 | Kangwon National University University-Industry Cooperation Foundation | Anti-l1cam antibodies and uses thereof |
TW202019473A (en) | 2018-07-02 | 2020-06-01 | 美商安進公司 | Anti-steap1 antigen-binding protein |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
JP2022503959A (en) | 2018-10-03 | 2022-01-12 | ゼンコア インコーポレイテッド | IL-12 heterodimer FC-fusion protein |
CN113164780A (en) | 2018-10-10 | 2021-07-23 | 泰洛斯治疗公司 | anti-LAP antibody variants and uses thereof |
WO2020112781A1 (en) | 2018-11-28 | 2020-06-04 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
WO2020117627A1 (en) | 2018-12-03 | 2020-06-11 | Bristol-Myers Squibb Company | Anti-ido antibody and uses thereof |
CN109762067B (en) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | Antibodies that bind human Claudin18.2 and uses thereof |
CN113396162A (en) | 2019-01-22 | 2021-09-14 | 百时美施贵宝公司 | Antibodies against IL-7R alpha subunit and uses thereof |
EP3930850A1 (en) | 2019-03-01 | 2022-01-05 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
WO2021011678A1 (en) | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
EP3999541A1 (en) | 2019-07-15 | 2022-05-25 | Bristol-Myers Squibb Company | Antibodies against human trem-1 and uses thereof |
CN114945409A (en) | 2020-01-13 | 2022-08-26 | 新免疫技术有限公司 | Methods of treating tumors with combinations of IL-7 proteins and bispecific antibodies |
US20230105029A1 (en) | 2020-02-27 | 2023-04-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antibodies binding il4r and uses thereof |
WO2021207449A1 (en) | 2020-04-09 | 2021-10-14 | Merck Sharp & Dohme Corp. | Affinity matured anti-lap antibodies and uses thereof |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
CN114685669A (en) | 2020-12-30 | 2022-07-01 | 和铂医药(苏州)有限公司 | Antibodies that bind TROP2 and uses thereof |
CN117157319A (en) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | Heterodimeric antibodies that bind CD3 and CLDN6 |
WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
Family Cites Families (155)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6A (en) * | 1836-08-10 | Thomas blanghard | ||
US4169888A (en) | 1977-10-17 | 1979-10-02 | The Upjohn Company | Composition of matter and process |
US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
CA1238907A (en) | 1984-02-21 | 1988-07-05 | Robert C. Kelly | 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds |
US4912227A (en) * | 1984-02-21 | 1990-03-27 | The Upjohn Company | 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds |
US4978757A (en) | 1984-02-21 | 1990-12-18 | The Upjohn Company | 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0271581B1 (en) | 1986-04-17 | 1993-01-13 | Kyowa Hakko Kogyo Co., Ltd. | Novel compounds dc-88a and dc-89a1 and process for their preparation |
US5332837A (en) * | 1986-12-19 | 1994-07-26 | The Upjohn Company | CC-1065 analogs |
ATE112279T1 (en) | 1986-12-19 | 1994-10-15 | Upjohn Co | CC-1065 ANALOGUE. |
JPS6428264A (en) * | 1987-07-21 | 1989-01-30 | Sumitomo Electric Industries | Production of superconducting material |
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5773435A (en) * | 1987-08-04 | 1998-06-30 | Bristol-Myers Squibb Company | Prodrugs for β-lactamase and uses thereof |
US4952394A (en) * | 1987-11-23 | 1990-08-28 | Bristol-Myers Company | Drug-monoclonal antibody conjugates |
US4994578A (en) * | 1987-11-27 | 1991-02-19 | Meiji Seika Kaisha, Ltd. | Certain anti-tumor duocarmycin antibiotics from streptomyces |
US5147786A (en) | 1988-04-22 | 1992-09-15 | Monsanto Company | Immunoassay for the detection of α-haloacetamides |
JP2642165B2 (en) * | 1988-07-22 | 1997-08-20 | 協和醗酵工業株式会社 | Novel DC-89 compound and method for producing the same |
US5084468A (en) * | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5194599A (en) | 1988-09-23 | 1993-03-16 | Gilead Sciences, Inc. | Hydrogen phosphonodithioate compositions |
US4915278A (en) * | 1988-11-03 | 1990-04-10 | Smith Kenneth W | Portable container |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
JP2598116B2 (en) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | New substance DC113 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3907562A1 (en) | 1989-03-09 | 1990-09-13 | Bayer Ag | ANTISENSE OLIGONUCLEOTIDS FOR INHIBITING THE TRANSACTIVATOR TARGET SEQUENCE (TAR) AND THE SYNTHESIS OF THE TRANSACTIVATOR PROTEIN (TAT) FROM HIV-1 AND THE USE THEREOF |
US5075181A (en) * | 1989-05-05 | 1991-12-24 | Kennametal Inc. | High hardness/high compressive stress multilayer coated tool |
WO1990013641A1 (en) | 1989-05-10 | 1990-11-15 | Sloan-Kettering Institute For Cancer Research | Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter |
WO1990015065A1 (en) | 1989-06-05 | 1990-12-13 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides and methods for preparing the same |
JP2510335B2 (en) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | DC-88A derivative |
US5187186A (en) * | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
DE69027443T2 (en) | 1989-10-24 | 1998-03-19 | Gilead Sciences Inc | OLIGONUCLEOTID ANALOGUE WITH NEW BINDINGS |
US5495009A (en) * | 1989-10-24 | 1996-02-27 | Gilead Sciences, Inc. | Oligonucleotide analogs containing thioformacetal linkages |
ATE269870T1 (en) | 1989-10-24 | 2004-07-15 | Isis Pharmaceuticals Inc | 2'-MODIFIED OLIGONUCLEOTIDES |
US5334528A (en) | 1989-10-30 | 1994-08-02 | The Regents Of The University Of California | Monoclonal antibodies to cyclodiene insecticides and method for detecting the same |
US5180819A (en) | 1989-12-22 | 1993-01-19 | The Trustees Of Columbia University In The City Of New York | Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof |
DE69133566T2 (en) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Formation of xenogenic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1991011535A1 (en) | 1990-01-30 | 1991-08-08 | Childrens Hospital Of Los Angeles | Inhibition of transcription by double-stranded oligonucleotides |
WO1991013080A1 (en) | 1990-02-20 | 1991-09-05 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
EP0527189A1 (en) | 1990-04-25 | 1993-02-17 | PHARMACIA & UPJOHN COMPANY | Novel cc-1065 analogs |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5137877B1 (en) * | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
EP0533838B1 (en) | 1990-06-11 | 1997-12-03 | NeXstar Pharmaceuticals, Inc. | Nucleic acid ligands |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DE69121334T2 (en) * | 1990-07-26 | 1997-03-20 | Kyowa Hakko Kogyo Kk | DC-89 derivatives as anti-tumor agents |
GB9017024D0 (en) | 1990-08-03 | 1990-09-19 | Erba Carlo Spa | New linker for bioactive agents |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0814159T3 (en) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgenic, non-human animals capable of forming heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992005186A1 (en) | 1990-09-20 | 1992-04-02 | Gilead Sciences | Modified internucleoside linkages |
AU8547691A (en) | 1990-09-21 | 1992-04-15 | Fred Hutchinson Cancer Research Center | Protein sequence-specific oligonucleotide sequences |
JPH04154298A (en) * | 1990-10-17 | 1992-05-27 | Pioneer Electron Corp | Speaker |
EP0558634A4 (en) | 1990-11-23 | 1995-06-28 | Gilead Sciences Inc | Triplex-forming oligomers containing modified bases |
AU9146591A (en) | 1990-12-10 | 1992-07-08 | Gilead Sciences, Inc. | Inhibition of transcription by formation of triple helixes |
US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
CA2104698A1 (en) | 1991-02-21 | 1992-08-22 | John J. Toole | Aptamers specific for biomolecules and methods of making |
US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
JPH0597853A (en) | 1991-10-07 | 1993-04-20 | Kyowa Hakko Kogyo Co Ltd | Hydrobromic acid salt of dc-89 derivative |
ATE463573T1 (en) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
DK0563475T3 (en) | 1992-03-25 | 2000-09-18 | Immunogen Inc | Conjugates of Cell Binding Agents and Derivatives of CC-1065 |
GB9314960D0 (en) * | 1992-07-23 | 1993-09-01 | Zeneca Ltd | Chemical compounds |
JP3514490B2 (en) * | 1992-08-21 | 2004-03-31 | 杏林製薬株式会社 | Trifluoromethylpyrroloindole carboxylate derivative and method for producing the same |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
US5324483B1 (en) | 1992-10-08 | 1996-09-24 | Warner Lambert Co | Apparatus for multiple simultaneous synthesis |
DE4314091A1 (en) | 1993-04-29 | 1994-11-03 | Boehringer Mannheim Gmbh | Immunological detection method for triazines |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5502037A (en) * | 1993-07-09 | 1996-03-26 | Neuromed Technologies, Inc. | Pro-cytotoxic drug conjugates for anticancer therapy |
US5773011A (en) | 1993-09-27 | 1998-06-30 | Gerbu Biotechnik Gmbh | Method of preparing a synergistic immunological adjuvant formulation |
US5786377A (en) | 1993-11-19 | 1998-07-28 | Universidad De Santiago De Compostela | Pyrrolo 3,2-E!indol derivatives, process for the preparation thereof and applications |
DE4410559A1 (en) * | 1994-03-26 | 1995-09-28 | Hoechst Ag | Oriented polyolefin film with amorphous polymer, process for its production and its use |
CA2165819C (en) | 1994-04-22 | 2005-12-27 | Nobuyoshi Amishiro | Dc-89 derivatives |
JPH07309761A (en) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | Method for stabilizing duocamycin derivative |
US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
JP4157600B2 (en) * | 1994-08-19 | 2008-10-01 | ラ レフィオン バロンネ | COMPOUND, COMPOSITION FOR PREPARATION, DIAGNOSTIC DEVICE CONTAINING THEM, AND USE THEREOF |
EP0786252A4 (en) | 1994-09-30 | 1998-01-07 | Kyowa Hakko Kogyo Kk | Antitumor agent |
US5580089A (en) * | 1994-10-11 | 1996-12-03 | Kolka; David B. | Vehicle stabilization system and method |
CN1051552C (en) * | 1994-11-29 | 2000-04-19 | 杏林制药株式会社 | Acrylamide derivatives and process for producing the same |
US5846645A (en) * | 1995-03-03 | 1998-12-08 | Asahi Glass Company Ltd. | Fluorocarbon resin-coated product |
WO1996035451A1 (en) | 1995-05-10 | 1996-11-14 | Kyowa Hakko Kogyo Co., Ltd. | Novel toxin complex |
US5686237A (en) | 1995-06-05 | 1997-11-11 | Al-Bayati; Mohammed A. S. | Use of biomarkers in saliva to evaluate the toxicity of agents and the function of tissues in both biomedical and environmental applications |
US5714586A (en) * | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5646298A (en) * | 1995-06-07 | 1997-07-08 | Procoron, Inc. | Cyclopropylindole prodrugs |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5545805A (en) * | 1995-06-07 | 1996-08-13 | Chesner Engineering, Pc | Enhanced stabilization of lead in solid residues using acid oxyanion and alkali-metal carbonate treatment |
US5769650A (en) * | 1995-06-19 | 1998-06-23 | Sumitomo Wiring Systems, Ltd. | Connector and cover therefor |
WO1997012862A1 (en) | 1995-10-03 | 1997-04-10 | The Scripps Research Institute | Cbi analogs of cc-1065 and the duocarmycins |
CA2187969C (en) | 1995-10-17 | 2006-05-30 | Dale L. Boger | A template for solution phase synthesis of combinatorial libraries |
ES2195036T3 (en) | 1995-12-22 | 2003-12-01 | Bristol Myers Squibb Co | RAMIFIED HYDRAZONE CONNECTORS. |
US5760072A (en) * | 1995-12-29 | 1998-06-02 | Pharmachemie B.V. | Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy |
US5685237A (en) * | 1996-01-16 | 1997-11-11 | David Lehrman | Extendable support foot for an ironing board |
US6143901A (en) | 1996-07-31 | 2000-11-07 | Genesoft, Inc. | Complex formation between dsDNA and pyrrole imidazole polyamides |
ES2244991T3 (en) | 1996-03-08 | 2005-12-16 | The Scripps Research Institute | ANALOGOSMCBI OF CC-1065 AND THE DUOCARMYCINS. |
US5843937A (en) * | 1996-05-23 | 1998-12-01 | Panorama Research, Inc. | DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents |
CA2255703A1 (en) | 1996-05-31 | 1997-12-04 | Dale L. Boger | Analogs of cc-1065 and the duocarmycins |
AU4134597A (en) * | 1996-09-03 | 1998-03-26 | Kyowa Hakko Kogyo Co. Ltd. | Dc-89 derivatives |
US6130237A (en) * | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
JPH1087666A (en) * | 1996-09-18 | 1998-04-07 | Kyorin Pharmaceut Co Ltd | Intermediate for producing duocarmycin sa and its derivative and production thereof |
US6759509B1 (en) * | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
WO1998025900A1 (en) | 1996-12-13 | 1998-06-18 | Shionogi & Co., Ltd. | Compounds having antitumor activity |
WO1998043663A1 (en) | 1997-03-28 | 1998-10-08 | The Scripps Research Institute | Sandramycin analogs |
AU7274898A (en) * | 1997-05-07 | 1998-11-27 | Bristol-Myers Squibb Company | Recombinant antibody-enzyme fusion proteins |
CA2290789A1 (en) | 1997-05-22 | 1998-11-26 | Dale L. Boger | Analogs of duocarmycin and cc-1065 |
US6316522B1 (en) | 1997-08-18 | 2001-11-13 | Scimed Life Systems, Inc. | Bioresorbable hydrogel compositions for implantable prostheses |
WO1999019298A1 (en) | 1997-10-14 | 1999-04-22 | The Scripps Research Institute | iso-CBI AND iso-CI ANALOGS OF CC-1065 AND THE DUOCARMYCINS |
AU1807999A (en) | 1997-12-08 | 1999-06-28 | Scripps Research Institute, The | Synthesis of cc-1065/duocarmycin analogs |
JP3045706B1 (en) | 1998-09-14 | 2000-05-29 | 科学技術振興事業団 | Compound for alkylating a specific base sequence of DNA and method for synthesizing the same |
US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
EP1144011B1 (en) | 1998-12-11 | 2010-03-10 | Coulter Pharmaceutical, Inc. | Prodrug compounds and process for preparation thereof |
CA2383358A1 (en) | 1999-08-31 | 2001-03-08 | Board Of Regents, The University Of Texas System | Methods and compositions of a novel serine protease inhibitor |
ES2274823T3 (en) | 1999-12-29 | 2007-06-01 | Immunogen, Inc. | COTOTOXIC AGENTS THAT INCLUDE DOXORRUBICINAS AND DAUNORRUBICINAS AND ITS THERAPEUTIC USE. |
DE10008089A1 (en) | 2000-02-22 | 2001-10-31 | Biotechnolog Forschung Gmbh | Production of tubulysin compounds comprises multi-stage process including condensation of N-methylpipecolinoyl-isoleucine with substituted thiazole-4-carboxylic acid derivative |
ATE362940T1 (en) | 2000-03-16 | 2007-06-15 | Genesoft Inc | CHARGED COMPOUNDS WITH A NUCLEIC ACID BINDING UNIT AND THEIR USES |
WO2001083482A1 (en) | 2000-05-03 | 2001-11-08 | The Scripps Research Institute | Dna alkylating agent and activation thereof |
JP4061819B2 (en) | 2000-05-12 | 2008-03-19 | 独立行政法人科学技術振興機構 | Method for synthesizing interstrand crosslinker |
EP1294403A2 (en) * | 2000-06-14 | 2003-03-26 | Corixa Corporation | Tripeptide prodrug compounds |
AU2001271301B2 (en) | 2000-06-14 | 2006-08-31 | Medarex, Inc. | Prodrug compounds cleavable by thimet oligopeptidase |
AU2001266853B2 (en) | 2000-06-14 | 2005-02-17 | Medarex, Inc. | Prodrug compounds with an oligopeptide having an isoleucine residue |
AU2001286727A1 (en) | 2000-08-24 | 2002-03-04 | Coulter Pharmaceutical, Inc. | Prodrugs activated by plasmin and their use in cancer chemotherapy |
EP1243276A1 (en) * | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6762179B2 (en) * | 2001-05-31 | 2004-07-13 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
CN101671335A (en) | 2001-05-31 | 2010-03-17 | 梅达莱克斯公司 | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
AU2002316539C1 (en) * | 2001-06-11 | 2008-10-30 | Medarex, Inc. | CD10-activated prodrug compounds |
CA2459308A1 (en) | 2001-09-07 | 2003-03-20 | Dale L. Boger | Cbi analogues of cc-1065 and the duocarmycins |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
JP2005511627A (en) | 2001-11-20 | 2005-04-28 | シアトル ジェネティクス,インコーポレーテッド | Treatment of immunological diseases using anti-CD30 antibodies |
TW557623B (en) * | 2001-11-28 | 2003-10-11 | Ind Tech Res Inst | Integrated demodulator for single-phase input frequency modulation signal |
US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
US6534660B1 (en) * | 2002-04-05 | 2003-03-18 | Immunogen, Inc. | CC-1065 analog synthesis |
US7776814B2 (en) | 2002-07-09 | 2010-08-17 | R&D-Biopharmaceuticals Gmbh | Tubulysin conjugates |
WO2004005327A1 (en) | 2002-07-09 | 2004-01-15 | Morphochem Ag Komb Chemie | Novel tubulysin analogues |
US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
ES2347959T3 (en) | 2003-02-20 | 2010-11-26 | Seattle Genetics, Inc. | ANTI-CD70-FARMACO ANTIBODIES CONJUGATES AND THEIR USE FOR CANCER TREATMENT. |
US20050026987A1 (en) * | 2003-05-13 | 2005-02-03 | The Scripps Research Institute | CBI analogues of the duocarmycins and CC-1065 |
BRPI0510909A2 (en) | 2004-05-19 | 2008-12-16 | Medarex Inc | cytotoxic drug-binder binding compound, pharmaceutical formulation, method for killing a cell and method for retarding or stopping tumor growth |
US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
US7180819B1 (en) | 2005-10-04 | 2007-02-20 | Lsi Logic Corporation | Converting dual port memory into 2 single port memories |
CA2641899A1 (en) | 2006-02-02 | 2007-08-09 | Syntarga B.V. | Water-soluble cc-1065 analogs and their conjugates |
-
2002
- 2002-05-31 CN CN200910173556A patent/CN101671335A/en active Pending
- 2002-05-31 AU AU2002303929A patent/AU2002303929B9/en not_active Ceased
- 2002-05-31 IL IL15418302A patent/IL154183A0/en unknown
- 2002-05-31 KR KR10-2003-7001398A patent/KR20030033007A/en active Search and Examination
- 2002-05-31 US US10/160,972 patent/US7129261B2/en not_active Expired - Lifetime
- 2002-05-31 US US10/161,233 patent/US6989452B2/en not_active Expired - Lifetime
- 2002-05-31 EP EP02731994A patent/EP1434778A4/en not_active Withdrawn
- 2002-05-31 EP EP10178144A patent/EP2266986A1/en not_active Withdrawn
- 2002-05-31 US US10/161,234 patent/US7087600B2/en not_active Ceased
- 2002-05-31 WO PCT/US2002/017210 patent/WO2002096910A1/en active Application Filing
- 2002-05-31 JP JP2003500089A patent/JP4961095B2/en not_active Expired - Lifetime
- 2002-05-31 CN CN02802159A patent/CN1463270A/en active Pending
- 2002-05-31 CA CA2448319A patent/CA2448319C/en not_active Expired - Fee Related
- 2002-05-31 MX MXPA03011094A patent/MXPA03011094A/en active IP Right Grant
- 2002-05-31 NZ NZ529788A patent/NZ529788A/en not_active IP Right Cessation
-
2003
- 2003-01-29 IL IL154183A patent/IL154183A/en not_active IP Right Cessation
-
2005
- 2005-06-21 US US11/133,970 patent/US7498302B2/en not_active Expired - Lifetime
- 2005-09-12 US US11/224,580 patent/US7507420B2/en not_active Expired - Lifetime
-
2008
- 2008-05-23 US US12/126,731 patent/USRE41252E1/en not_active Expired - Lifetime
-
2009
- 2009-03-02 US US12/396,266 patent/US8034959B2/en not_active Expired - Fee Related
- 2009-03-04 US US12/397,834 patent/US7977465B2/en not_active Expired - Fee Related
- 2009-04-07 JP JP2009092549A patent/JP2009155342A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2448319A1 (en) | Cytotoxins, prodrugs, linkers and stabilizers useful therefor | |
CN100522249C (en) | Elogated and multiple spacers in activatible prodrugs | |
ES2404685T3 (en) | Heterobifunctional poly (ethylene glycol) derivatives and methods for their preparation | |
ES2371865T3 (en) | CONJUGATES OF HYDROXIALQUILALMIDÓN-ACTIVE PRINCIPLE. | |
US4385169A (en) | Reactive alpha amino acid polymer | |
ES2834916T3 (en) | Polylysine dendrimer targeted therapeutic agent | |
EP1745802A1 (en) | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes | |
DK0757049T3 (en) | camptothecin | |
ID25979A (en) | KOMTOTESIN DEGREE (Fraction from P-963785) | |
CY1105829T1 (en) | ARYL-BORONIC ACIDS, FOR OBESITY HOSPITAL | |
EP2678037A1 (en) | Branched linker for protein drug conjugates | |
EA200001217A1 (en) | DRUG COMPLEX | |
RU95112841A (en) | Polymeric conjugate, method of its synthesis, derivative of 20-o-acylaminocamptothecine and method of its synthesis, pharmaceutical composition | |
CA2723664A1 (en) | Hydrazine-based and carbonyl-based bifunctional crosslinking reagents | |
AR067837A1 (en) | FARMACO-LIGANDO CONJUGATES AND PHARMACO-SCINDIBLE SUBSTRATES, COMPOSITIONS CONTAINING THEM; USEFUL IN TUMORS AND CANCER TREATMENT | |
KR920008065A (en) | Peptide Compounds, Methods For Making Them, And Pharmaceutical Compositions Containing Them | |
CA2462085A1 (en) | Cytotoxic agents | |
DE69724964D1 (en) | TARGETED DRUG DELIVERY FOR ZULPHONAMIDE DERIVATIVES | |
DE3784799D1 (en) | MALONIC ACID DERIVATIVES AND THEIR SYNTHESIS METHODS. | |
ES2792598T3 (en) | Methods for preparing conjugates from disulfide-containing proteins | |
FI952141A0 (en) | Molecular labeling using 2-hydraninopyridine derivatives | |
JP2005514505A (en) | Preparation and use of multi-arm dendritic and functional PEG | |
ES2402614A1 (en) | Controlled synthesis of polyglutamates with low polydispersity and versatile architectures | |
JP2002520288A5 (en) | ||
KR880011082A (en) | β-amino ethyl-substituted phenyl compounds and their pharmaceutically acceptable salts and amides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20220301 |
|
MKLA | Lapsed |
Effective date: 20200831 |